HistoSonics Edison® Histotripsy System Treats First Pancreatic Tumor Patients in GANNON Trial December 17, 2024
Edison Investment Research publishes an updated research note of Cereno Scientific and an executive CEO interview with Sten R. Sörensen November 28, 2024
Edison Investment Research publishes Executive interview with Sten R. Sörensen, CEO, Cereno Scientific, on positive topline Phase IIa results October 7, 2024
Edison Investment Research increases valuation of Cereno Scientific to 3.9 BSEK or SEK 13.9 SEK/share after positive topline data October 2, 2024
